RxDoctor Payments DataLook up a doctor →

Maitri Patel, MD

Child & Adolescent Psychiatry · Framingham, MANPI 1912945213

Payments from drug & device makers

$277,107in general payments, 2019–2025

Across 792 payments — averaging $349.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironshore Pharmaceuticals Inc.$159K
  • AbbVie$52K
  • Collegium Pharmaceutical, Inc.$43K
  • Takeda Pharmaceuticals U.S.A., Inc.$15K
  • Neuronetics, Inc.$2K
  • Sunovion Pharmaceuticals Inc.$866
  • plus $5K from 20 others

What the payments were for

  • Consulting fees$24,4439%
  • Speaking & faculty fees$191,90369%
  • Travel & lodging$44,04216%
  • Food & beverage$16,6076%
  • Education$1120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$277,107 in reported general payments places this provider in the 95th percentile of 104 child & adolescent psychiatry providers in Massachusetts.

See all child & adolescent psychiatry providers in Massachusetts

Medicare billing

Part B allowed, 2024
$33,036
Medicare patients
22
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon13$297,793
IngrezzaValbenazine Tosylate24$192,678
VraylarCariprazine Hcl16$23,804
Cotempla Xr-OdtMethylphenidate12$12,640
TrintellixVortioxetine Hydrobromide14$10,635
VyvanseLisdexamfetamine Dimesylate16$7,225
Lamotrigine25$1,281
Clonidine Hcl ErClonidine Hcl13$977
Methylphenidate ErMethylphenidate Hcl12$742
Sertraline Hcl44$649
Mirtazapine12$437
Buspirone Hcl11$363
Clonazepam15$269
Escitalopram Oxalate11$237
Lurasidone Hcl15$177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Hetlioz$116$297,79313 claims
Neurocrine Biosciences, Inc.Ingrezza$548$192,67824 claims
AbbVieVraylar$52,004$23,80416 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$14,577$17,86030 claims
Neos Therapeutics, LPCotempla Xr-Odt$824$12,64012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 104 child & adolescent psychiatry providers in Massachusetts.

Other child & adolescent psychiatry in Framingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →